Cliny PEG Gastrostomy kits of Create Medic launched in India by Medinippon, GNCorp sister company 11Aug2023 Ja
Nichi Glucan range of products
2023-04: (AFO-202, N-163) Aging Res & LifestyleIkewaki N, Sonoda T, Kurosawa G, Iwasaki M, Dedeepiya VD, Senthilkumar R, Preethy S, Abraham S. Beta 1,3-1,6 glucans produced by two novel strains of Aureobasidium pullulans exert immune and metabolic beneficial effects in healthy middle-aged Japanese men: Results of an exploratory randomized control study doi: 10.14283/jarlife.2023.11
2023-03: (AFO-202,N-163) GEORGIAN MEDICAL NEWS No 3 (336) 2023
S Preethy , N Yamamoto , N Liem , S Bharatidasan , M Iwasaki , S Abraham. Role of gut microbiome homeostasis, integrity of the intestinal epithelial cells, and the (endogenous) butyrate in enduring a healthy long lifedoi: 10.1159/000527728
2023-02: (AFO-202) JAMA Pediatr Published online April 03, 2023
Zeyan Liew, Qi Meng, Qi Yan, et al.
Gut microbiome evaluation in children with autism spectrum disorder after increased maternal lithium consumption, may throw further insight. Comment to: Liew Z, Meng Q, Yan Q, et al. Association Between Estimated Geocoded Residential Maternal Exposure to Lithium in Drinking Water and Risk for Autism Spectrum Disorder in Offspring in Denmark. doi: 10.1001/jamapediatrics.2023.0346
2023-01: (AFO-202) Vaccine 2023Ikewaki N, Kurosawa G, Levy GA, Preethy S, Abraham S.
Antibody dependent disease enhancement (ADE) after COVID-19 vaccination and Beta Glucans as a safer strategy in management doi: 10.1016/j.vaccine.2023.03.005.
2022-10:（AFO-202） Med Princ Pract
Preethy S, Raghavan K, Ikewaki N, Abraham SJ.
Qualitative Evaluation of α-Synuclein – A Critical Step in Unraveling the Complexities of Autism Spectrum Disorder
2022-09:（AFO-202, N-163） BMJ Open Gastroenterology
Preethy S, Ikewaki N, Levy GA, Raghavan K, Dedeepiya VD, Yamamoto N, Srinivasan S, Ranganathan N, Iwasaki M, Senthilkumar R, Abraham SJK.
Two unique biological response-modifier glucans beneficially regulating gut microbiota and faecal metabolome in a non-alcoholic steatohepatitis animal model, with potential for applications in human health and disease
2022-08:（AFO-202, N-163） Frontiers in Immunology
Preethy S, Raghavan K, Dedeepiya VD, Suryaprakash V, Ikewaki N, Ikeue Y, Nagataki M, Iwasaki M, Senthilkumar R, Abraham S.
Beneficial immune regulation by biological response modifier glucans in COVID-19 and their envisaged potentials in the management of sepsis
2022-07:（AFO-202） Journal of Alzheimer’s Disease
Preethy S, Ranganathan N, Raghavan K, Dedeepiya VD, Ikewaki N, Abraham S.
Integrating the Synergy of the Gut Microbiome into Regenerative Medicine: Relevance to Neurological Disorders
2022-06:（AFO-202） Journal of Food Biochemistry
Ikewaki, N., Kurosawa, G., Kisaka, T. and Abraham, S.J.K. (2022),
Controlled modulation of all the arms of the immunity including innate immunity by biological response modifier glucans, a simple yet potential nutritional supplement strategy to fight COVID-19
2022-05:（AFO-202） Journal of Alzheimer’s disease
Raghavan K, Dedeepiya VD, Yamamoto N, Ikewaki N, Sonoda T, Kurosawa G, Iwasaki M,Kandaswamy R, Senthilkumar R, Preethy S, Abraham SJK.
Benefits of Gut Microbiota Reconstitution by Beta 1,3-1,6 Glucans in Subjects with Autism Spectrum Disorder and Other Neurodegenerative Diseases
2022-04: (AFO-202, N-163) Journal of Diabetes and Metabolic Disorders
Ikewaki N, Onaka T, Ikeue Y, Nagataki M, Kurosawa G, Dedeepiya VD, Rajmohan M, Vaddi S, Senthilkumar R, Preethy S, Abraham SJK.
Beneficial effects of 1,3–1,6 β-glucans produced by Aureobasidium pullulans on non-esterified fatty acid levels in diabetic KKAy mice and their potential implications in metabolic dysregulation
2022-03: (AFO-202, N-163) Brain and Behavior
Raghavan K, Dedeepiya VD, Kandaswamy R, Balamurugan M, Ikewaki N, Sonoda T, Kurosawa K, Iwasaki M, Preethy S, Abraham SJK.
Improvement of sleep and melatonin in children with autism spectrum disorder after β-1,3/1,6-glucan consumption: An open-label prospective pilot clinical study
2022-02: (AFO-202, N-163） Journal of Clinical and Experimental Hepatology
Nobunao Ikewaki, Gary A. Levy, Gene Kurosawa, Masaru Iwasaki, Vidyasagar D. Dedeepiya, Suryaprakash Vaddi
Rajappa Senthilkumar, Senthilkumar Preethy, Samuel J.K. Abraham
Hepatoprotective Effects of Aureobasidium pullulans Derived β 1,3–1,6 Glucans in a Murine Model of Non-alcoholic Steatohepatitis
2022-01: (AFO-202) BMJ Neurology Open
Raghavan K, Dedeepiya VD, Ikewaki N, Sonoda T, Iwasaki M, Preethy S, Abraham SJK.
Improvement of behavioural pattern and alpha-synuclein levels in autism spectrum disorder after consumption of a beta-glucan food supplement in a randomized, parallel-group pilot clinical study.
2021-05: (AFO-202, N-163) Clinical Immunology Communications
Ikewaki N, Raghavan K, Dedeepiya VD, Suryaprakash V, Iwasaki M, Preethy S, senthilkumar R, Abraham SJK.
Beneficial immune-regulatory effects of novel strains of Aureobasidium pullulans AFO-202 and N-163 produced beta glucans in Sprague Dawley rats
2021-04: (AFO-202) Oncology Reports
Ikewaki N, Dedeepiya VD, Raghavan K, Rao K, Vaddi S, Osawa H, Kisaka T, Kurosawa G, Srinivasan S, Ganesakumar SRB, Senthilkumar R, Iwasaki M, Preethy S, Abraham SJK.
β‑glucan vaccine adjuvant approach for cancer treatment through immune enhancement (B‑VACCIEN) in specific immunocompromised populations (Review)
2021-03: (AFO-202, N-163) Biomedicine & Pharmacotherapy
Raghavan K, Dedeepiya VD, Suryaprakash V, Rao KS, Ikewaki N, Sonoda T, Levy GA, Iwasaki M, Senthilkumar R, Preethy S, Abraham SJK.
Beneficial Effects of novel Aureobasidium Pullulans strains produced Beta-1,3-1,6 Glucans on Interleukin-6 and D-Dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study
2021-02: (AFO-202) Human Vaccines & Immunotherapeutics
Ikewaki N, Iwasaki M, Kurosawa G, Rao KS, Beitia JL, Preethy S, Abraham SJK.
β-Glucans: Wide-spectrum Immune-balancing Food-supplement-based Enteric (β-WIFE) Vaccine Adjuvant Approach to COVID-19
2021-01: (AFO-202) Frontiers in Immunology
Ikewaki N, Dedeepiya VD, Iwasaki M, Abraham SJK.
Commentary: Beyond “TRIM” benefits of β-glucan by blood glucose and lipid balancing potentials in its defense Against COVID-19
2020-03: (AFO-202) Frontiers in Immunology
Rao K-S, Suryaprakash V, Senthilkumar R, Preethy S, Katoh S, Ikewaki N, Abraham SJK.
Role of Immune Dysregulation in Increased Mortality Among a Specific Subset of COVID-19 Patients and Immune-Enhancement Strategies for Combatting Through Nutritional Supplements
2020-02: (AFO-202) Thrombosis Journal
Ikewaki N, Rao KS, Archibold AD, Iwasaki M, Senthilkumar R, Preethy S, Katoh S, Abraham SJK.
Coagulopathy associated with COVID-19 – Perspectives & Preventive strategies using a Biological Response Modifier Glucan. Thromb J. 2020. doi: 10.1186/s12959-020-00239-6
2020-01: (AFO-202) Journal of Diabetes & Metabolic Disorders volume
Ikewaki N, Iwasaki M, Abraham SJK.
Biological response modifier glucan through balancing of blood glucose may have a prophylactic potential in COVID-19 patients.
2014-01: (AFO-202) Journal of Dietary Supplement
Jegatheesan Saravana Ganesh,Yegneswara Yellury Rao,Ratnagiri Ravikumar,Gosalakkal A. Jayakrishnan,Masaru Iwasaki,Senthilkumar Preethy &Samuel JK AbrahamIkewaki N, Iwasaki M, Abraham SJK.
Beneficial effects of Black yeast derived 1-3, 1-6 beta glucan- Nichi Glucan in a dyslipidemic individual of Indian origin A case report.
2012-01: (AFO-202) Case Reports in Medicine
Dedeepiya V, Sivaraman G,Venkatesh A, Preethy S, Abraham SJK.
Potential Effects of Nichi Glucan as a Food Supplement for Diabetes Mellitus and Hyperlipidemia; Preliminary Findings from the Study on Three Patients from India
Raghavan K, Dedeepiya VD, Yamamoto N, Ikewaki N, Iwasaki M, Dinassing A, Senthilkumar R, Preethy S, Abraham SJK.
Randomised trial of Aureobasidium pullulans-produced beta 1,3-1,6-glucans in patients with Duchenne muscular dystrophy: Favourable changes in gut microbiota and clinical outcomes indicating their potential in epigenetic manipulation.
medRxiv 2022.12.09.22283273; doi: 10.1101/2022.12.09.22283273
Preethy S, Aoki Y, Minegishi K, Senthilkumar R, Abraham S.
Resolution of fibrosis in mdx dystrophic mouse after oral consumption of N-163 strain of Aureobasidium pullulans produced biological response modifier β-glucan (BRMG).
bioRxiv 2022.11.17.516628; doi: 10.1101/2022.11.17.516628
３） (AFO-202, N-163)
Pushkala S, Seshayyan S, Theranirajan E, Sudhakar D, Raghavan K, Dedeepiya VD, Ikewaki N,Iwasaki M, Preethy S, Abraham S.
Efficient control of IL-6, CRP and Ferritin in Covid-19 patients with two variants of Beta-1,3-1,6 glucans in combination, within 15 days in an open-label prospective clinical trial.
Raghavan K, Dedeepiya VD, Srinivasan S, Pushkala S, Subramanian S, Ikewaki N, Iwasaki M, Senthilkumar R, Preethy S, Abraham S.
Disease-modifying immune-modulatory effects of the N-163 strain of Aureobasidium pullulans-produced 1,3-1,6 Beta glucans in young boys with Duchenne muscular dystrophy: Results of an open-label, prospective, randomized, comparative clinical study
Ikewaki N, Sonoda T, Kurosawa G, Iwasaki M, Dedeepiya VD, Senthilkumar R, Preethy S, Abraham SJK.
Immune and metabolic beneficial effects of Beta 1,3-1,6 glucans produced by two novel strains of Aureobasidium pullulans in healthy middle-aged Japanese men: An exploratory study
Increased yield of Beta 1,3-1,6 glucans, produce of AFO-202 strain of Aureobasidium Pullulans, using improvised techniques by Japanese scientists
Japanese scientists, research collaborators to Nichi-in Centre for Regenerative Medicine (NCRM) have reported an increased yield of Beta 1,3-1,6 glucans in the produc
Neu REFIX B-glucans improve Anti-aging Butyrate & gut microbiome
Neu REFIX beta glucans improving Multiple Sclerosis patients’ gut microbiome awarded as the best poster in 6th Microbiome Asia Conference in Tokyo 26~27 April 2023
Neu REFIX beta glucans improving Multiple Sclerosis patients’ gut microbiome awarded as the best poster